Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.37 USD
Change Today +0.39 / 3.55%
Volume 17.7K
MSON On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

misonix inc (MSON) Key Developments

Misonix Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended June 30, 2015

Misonix Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended June 30, 2015. For the quarter, the company reported net sales of $6,749,436 compared to $5,578,147 a year ago. Loss from operations was $42,253 compared to income from operations of $234,238 a year ago. Income from continuing operations before income taxes was $984,113 compared to $1,404,154 a year ago. Net income from continuing operations was $3,824,968 or $0.50 per diluted share compared to $1,387,400 or $0.19 per diluted share a year ago. Net income was $3,832,437 or $0.46 per diluted share compared to $1,389,193 or $0.18 per diluted share a year ago. The increase was primarily attributable to a 48% increase in BoneScalpel revenue to $3.7 million and a 99% increase in SonicOne revenue to $985,000. For the year, the company reported net sales of $22,204,578 compared to $17,060,435 a year ago principally attributable to an increase of 44% in BoneScalpel revenue to $11.1 million, a 14% increase in SonaStar revenue to $7.2 million and a 47% increase in SonicOne revenue to $3.3 million. Loss from operations was $1,714,939 compared to $2,548,964 a year ago. Income from continuing operations before income taxes was $5,304,056 compared to $1,157,210 a year ago. Net income from continuing operations was $15,304,056 or $0.70 per diluted share compared to $1,126,580 or $0.15 per diluted share a year ago. Net income was $5,571,171 or $0.69 per diluted share compared to $1,393,299 or $0.19 per diluted share a year ago.

Misonix, Inc. to Report Q4, 2015 Results on Aug 20, 2015

Misonix, Inc. announced that they will report Q4, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 20, 2015

Misonix, Inc., Q4 2015 Earnings Call, Aug 20, 2015

Misonix, Inc., Q4 2015 Earnings Call, Aug 20, 2015

Misonix, Inc. Unveils New SonicOne O.R. App to Highlight Advantages of Ultrasonic Wound Debridement in Acute and Chronic Wounds

Misonix, Inc. announced the launch of its SonicOne O.R. app for iPad mobile devices. The new iPad app was designed to educate users on the extensive benefits of ultrasonic wound debridement using the SonicOne technology. Users can explore the science behind the SonicOne O.R. with 3D animation of the innovative ultrasound technology, witness the macro and microscopic interaction of ultrasound in a wound environment, and observe the surgical technique used for debriding a wound in the 3D wound animation. The app also contains extensive material on SonicOne O.R.'s clinical and economic benefits, key publications and endorsements from distinguished surgeons who have made SonicOne a standard of care in their practice.

Misonix, Inc. Launches Faster Faster SonicOne Ultrasonic Debridement Procedure

Misonix, Inc. announced that it has released a newly-developed, faster SonicOne O.R. Ultrasonic wound debridement procedure. The procedure is enabled by a new single-use disposable debridement probe with increased ultrasonic amplitude that allows surgeons using the SonicOne device to potentially reduce the operating room time necessary to complete a procedure by up to 50%. The SonicOne O.R. System is an innovative ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. The new SonicOne procedure will be sold and distributed through the Misonix sales team and the company's distributor network in the United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSON:US $11.37 USD +0.39

MSON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.30 USD -0.06
IRIDEX Corp $6.89 USD +0.17
MGC Diagnostics Corp $5.25 USD +0.22
NanoVibronix Inc $4.20 USD 0.00
Utah Medical Products Inc $52.89 USD +2.26
View Industry Companies
 

Industry Analysis

MSON

Industry Average

Valuation MSON Industry Range
Price/Earnings 17.4x
Price/Sales 4.0x
Price/Book 3.7x
Price/Cash Flow 15.8x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MISONIX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.